drugset / Trial / NCT03066739

Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia

NCT03066739 ↗

Phase 2 Terminated 8 enrolled University of California, Irvine
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate whether using ultra-low dose naloxone, an opioid antagonist, has the potential to block remifentanil-induced hyperalgesia and tolerance following surgery. There are 3 study groups: (1) low dose remifentanil (LO, 0.1 micrograms/kg/mL), (2) high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL), or (3) high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone). The hypothesis of the study is that occurrence of remifentanil-induced hyperalgesia (low score in mechanical pain threshold) in the HN group will be lower than in the HI group.

Timeline

Start
2023-02-25
Primary completion
2024-12-10
Completion
2025-12-01

Outcome

Outcome not reported

Stopped (Enrollment): “Study terminated early due to low enrollment. Only 8 participants enrolled out of the target 105.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naloxone Small molecule 0.004 unknown —
Comparator Remifentanil Small molecule 0.1 unknown —
Comparator Remifentanil Small molecule 0.4 mg —
Comparator Remifentanil Small molecule 0.4 unknown —

Indications

No indication recorded.